Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 16, 2011

Sanofi and Audion Ink Hearing Loss Research Deal

  • Sanofi entered into a two-year research collaboration with Audion Therapeutics to develop treatments for hearing loss. The companies say that they will optimize small molecules by using a regenerative medicine approach.

    The work will utilize technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory by investigator and Audion co-founder Albert Edge, Ph.D. Under terms of the agreement, Sanofi has an option to license technology rights from Audion related to research conducted under the collaboration.

    Audion says it has gathered detailed knowledge of inner ear molecular biology to enable the development of drugs that can regenerate the lost hair cells and potentially restore a level of hearing. The firm is developing an IP portfolio that encompasses new molecules, delivery systems, and drug discovery tools for hearing and hearing loss research.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »